Cue the relief in Basel: Roche’s Rituxan just got another biosim break. Rival drugmaker Novartis says its knockoff version didn’t pass muster at the FDA, and that setback follows another for would-be Rituxan copycat Celltrion. The upshot? No U.S. biosims are likely this year.

Bron: FiercePharma | lees verder..